Success Stories: Chinese Research Health Scientist Secures NIW and EB1A Approvals for Advancing Pharmaceutical Science

“Thank you very much for helping and for your expertise! It has been a pleasure to work with you!”

Case Summary:      

We are pleased to share the dual NIW and EB1A approvals of a research health scientist from China. At the time of filing, she was conducting research in the United States that combines pharmacoepidemiology, pharmacoeconomics, and health outcomes science. Her work identifies treatment risks, prescribing patterns, and patient outcomes in chronic diseases, aiming to inform better diagnostics, therapeutic strategies, and healthcare policies. Her publication record, growing citation impact, and peer review service made her a compelling candidate for both NIW and EB1A approval.

Research with National Importance

The client’s proposed endeavor is focused on uncovering disease mechanisms and treatment risks to improve patient care. Her studies have examined the safety of proton pump inhibitors in liver disease patients, prescribing cascades in older adults, hospital readmissions in COPD patients, and the quality-of-life effects of endocrine therapy in breast cancer treatment. These findings directly address public health challenges in the United States, such as the rising burden of chronic diseases and the need for cost-effective care.

By combining health economics with epidemiological methods, her research provides tools for early diagnosis, more efficient healthcare delivery, and targeted interventions. This work aligns with U.S. priorities in public health innovation and directly supports efforts to reduce costs while enhancing outcomes.

Academic Record and Recognition

The client holds a Ph.D. in pharmaceutical outcomes and policy and has authored 26 peer-reviewed journal articles (10 as first author and 1 accepted), along with 20 abstracts (9 first-authored). Her publications in journals such as JAMA Network Open, Hepatology, and Morbidity and Mortality Weekly Report have been cited 187 times, with several ranked among the top 10–20% most cited in clinical medicine for their years.

In addition to her publications, she has completed at least 21 peer reviews for leading journals, including Annals of Internal Medicine and American Journal of Preventive Medicine. This recognition underscores her standing as a trusted contributor whose judgment is relied upon by respected outlets.

Expert Support

Independent experts strongly endorsed her research, emphasizing its influence and relevance to national priorities.

One recommender wrote:

“Overall, [Client] has made substantial advancements in disease management and control in the United States. Considering her novel project outcomes, number of published and peer-reviewed articles, and consistent peer review involvement, it is clear that she represents an irreplaceable asset to the pharmaceutical sciences community.”

This testimony highlights the originality of her contributions and their real-world impact.

Dual Approvals and Outlook

The I-140 NIW petition was filed on October 13, 2022, and approved on February 2, 2023. Her EB1A petition, filed on March 4, 2024, was later upgraded to premium processing and approved on January 30, 2025.

With NAILG’s guidance, the client secured approval under both the NIW and EB1A categories. She is now positioned to continue advancing pharmaceutical science in the United States, where her work will drive innovation in treatment strategies and reinforce U.S. leadership in health outcomes research.